Brain Cancer @ Leeds

Dr Mark Teo – Clinical Lecturer

markContact Information

Dr Mark Teo
NIHR Academic Clinical Lecturer in Clinical Oncology
Translational Neuro-Oncology
Leeds Institute of Cancer and Pathology
Wellcome Trust Brenner Building
St James’s University Hospital
Leeds LS9 7TF
United Kingdom

tel: +44 (0) 113 343 7853
email: M.T.W.Teo@leeds.ac.uk

Overview

I am an NIHR academic clinical lecturer undertaking post-doctoral research while completing my specialist clinical training in clinical oncology. My research interest is the role of DNA repair in radiotherapy response in brain tumours and if these repair pathways can be influenced to improve radiotherapy treatment outcomes. I am currently exploring the microhomology end-joining DNA double strand break repair pathway in glioblastoma and its role in tumour radiosensitivity.

Resume

Publications

Prestwich RJ, Teo MT, Gilbert A, Williams G, Dyker KE, Sen M, Long term swallow function post-chemoradiotherapy for oropharyngeal cancer: the influence ofa prophylactic gastrostomy or reactive nasogastric tube. Clin Oncol (R Coll Radiol). Accepted for publication

Teo M, Karakaya E, Young CA, Dyker KE, Coyle C, Sen M, and Prestwich RJ, The Efficacy of Induction Chemotherapy with Docetaxel, Cisplatin and 5-fluorouracil Combined with Cisplatin Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: A Matched Pair Analysis. Clin Oncol (R Coll Radiol), 2013. 25(11): p. 647-53.

Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, and Kiltie AE, Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res, 2013. 73(5): p. 1611-20.

Williams GF, Teo MT, Sen M, Dyker KE, Coyle C, and Prestwich RJ, Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy? Oral Oncol, 2012. 48(5): p. 434-40.

Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, Landi S, Bishop DT, and Kiltie AE, The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 2012. 33(3): p. 581-6.

Qiao B, Ansari AH, Scott GB, Sak SC, Chambers PA, Elliott F, Teo MT, Bentley J, Churchman M, Hall J, Taylor CF, Bishop TD, Knowles MA, and Kiltie AE, In vitro functional effects of XPC gene rare variants from bladder cancer patients. Carcinogenesis, 2011. 32(4): p. 516-21.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Jr., Grubb R, 3rd, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, M DG-P, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Jr., Silverman DT and Chanock SJ, A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet, 2010. 42(11): p. 978-84.

Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, and Kiltie AE, MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res, 2010. 70(18): p. 7017-26.

© Copyright Leeds 2017